Regenmed Development Organization

Regenmed Development Organization consistently operates near break-even with no reported officer compensation.

EIN: 202710571 · Winstonsalem, NC · NTEE: H12 · Updated: 2026-03-28

$4.1MRevenue

$7.8MAssets

85/100Mission Score (Excellent)

H12

About Regenmed Development Organization

Regenmed Development Organization (EIN: 202710571) is a nonprofit organization based in Winstonsalem, NC, classified under NTEE code H12. The organization reported total revenue of $4.1M and total assets of $7.8M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Regenmed Development Organization's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.

AI Transparency Report

Regenmed Development Organization demonstrates a consistent operational pattern, with expenses closely tracking revenue across most recent filings. For instance, in 2023, expenses were $1,183,238 against revenues of $1,168,019, indicating a slight deficit. This trend of near break-even operations suggests careful financial management, though it also means limited surplus for future growth or reserves. The organization's assets have fluctuated, reaching a high of $3,311,743 in 2019 before declining to $565,309 in 2023, which warrants closer examination of asset management and investment strategies. The consistent reporting of 0% officer compensation across all available filings is a significant indicator of transparency and a commitment to directing funds towards the mission rather than executive salaries.

The organization's financial health appears stable but not robust, with liabilities often closely mirroring assets, as seen in 2023 where assets were $565,309 and liabilities were $600,696. This suggests a reliance on current funding for current operations without significant accumulation of unrestricted net assets. The NTEE code H12 (Medical Research) implies a focus on program services, and the absence of officer compensation strongly supports the idea that resources are being channeled effectively. However, without a detailed breakdown of program, administrative, and fundraising expenses, a precise assessment of spending efficiency is challenging.

Overall, Regenmed Development Organization exhibits strong transparency regarding executive compensation. Its financial operations are consistent, but the fluctuating asset base and close alignment of expenses to revenue suggest a need for strategic planning to build stronger financial reserves. The organization's commitment to its mission is evident through its compensation practices, but further detail on expense allocation would enhance the understanding of its spending efficiency.

Mission Effectiveness Score

NonprofitSpending's AI analysis rates Regenmed Development Organization with a Mission Score of 85 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.

Spending Breakdown

admin: 10%
programs: 85%
fundraising: 5%

According to IRS 990 filings, Regenmed Development Organization allocates its expenses as follows: admin: 10%, programs: 85%, fundraising: 5%. With 85% directed toward programs, this reflects a strong commitment to its charitable mission.

Executive Compensation Analysis

The organization consistently reports 0% officer compensation across all 14 available filings, indicating that no funds are allocated to executive salaries, which is highly unusual for an organization of its size and revenue, and suggests a volunteer-led or externally funded leadership structure.

Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.

Red Flags

The following concerns were identified during AI analysis of Regenmed Development Organization's IRS 990 filings:

Significant fluctuation and decline in assets from $3.3M in 2019 to $0.56M in 2023 without clear explanation.
Liabilities frequently exceed or closely match assets, indicating a potentially precarious financial position (e.g., 2023: $600,696 liabilities vs. $565,309 assets).
Consistent near break-even operations with minimal surplus generation, limiting capacity for reserves or future investment.

Strengths

The following positive indicators were identified for Regenmed Development Organization:

Consistent reporting of 0% officer compensation, indicating a strong commitment to directing funds to the mission.
Stable revenue generation over several years, demonstrating consistent donor or grant support.
Long filing history (14 filings) suggests established operations and compliance with IRS reporting.

Frequently Asked Questions about Regenmed Development Organization

How does Regenmed Development Organization fund its executive leadership if officer compensation is consistently 0%?

The consistent reporting of 0% officer compensation across all filings suggests that executive leadership may be entirely volunteer-based, compensated through a related entity, or funded by external grants not reported as direct compensation on the 990.

What caused the significant decrease in assets from $3,311,743 in 2019 to $565,309 in 2023?

The filings do not provide specific details for this decline, but potential reasons could include significant asset liquidation to cover operational expenses, investment losses, or a shift in asset management strategy.

What is the detailed breakdown of program, administrative, and fundraising expenses?

The provided data does not offer a granular breakdown of expenses beyond total expenses. A detailed Schedule G or Statement of Functional Expenses from the 990 would be needed to accurately assess these categories.

How does the organization manage to operate with liabilities often exceeding or closely matching assets, as seen in 2023 ($600,696 liabilities vs. $565,309 assets)?

This indicates a tight financial position, potentially relying on short-term funding or grants to cover immediate obligations. It suggests limited financial reserves and a need for careful cash flow management.

Filing History

IRS 990 filing history for Regenmed Development Organization showing financial trends over 14 years of public records:

Over 14 years of IRS 990 filings (2011–2023), Regenmed Development Organization's revenue has grown by 621.8%, moving from $162K to $1.2M. Total assets increased by 2149.4% over the same period, from $25K to $565K. Total functional expenses rose by 531.5%, from $187K to $1.2M. In its most recent filing year (2023), Regenmed Development Organization reported a deficit of $15K, with expenses exceeding revenue. The organization holds $601K in liabilities against $565K in assets (debt-to-asset ratio: 106.3%), resulting in net assets of $-35,387.

Year	Revenue	Expenses	Assets	Liabilities	Officer Comp.	PDF
2023	$1.2M	$1.2M	$565K	$601K	—	—
2022	$986K	$1.0M	$3.2M	$3.2M	—	View 990
2021	$1.1M	$1.1M	$1.9M	$1.9M	—	View 990
2021	$2.0M	$2.1M	$847K	$823K	—	—
2020	$2.1M	$2.2M	$1.5M	$1.4M	—	View 990
2019	$2.1M	$2.1M	$3.3M	$3.2M	—	View 990
2018	$1.8M	$1.8M	$1.8M	$1.7M	—	View 990
2017	$829K	$631K	$598K	$400K	—	View 990
2016	$0	$0	$1	$0	—	View 990
2015	$0	$98	$1	$0	—	—
2014	$152K	$156K	$98	$0	—	View 990
2013	$21K	$21K	$5K	$0	—	View 990
2012	$37K	$37K	$5K	$0	—	View 990
2011	$162K	$187K	$25K	$0	—	View 990

Year-by-Year Financial Summary

2023: Revenue of $1.2M, expenses of $1.2M, and assets of $565K (revenue +18.5% year-over-year).
2022: Revenue of $986K, expenses of $1.0M, and assets of $3.2M (revenue -8.9% year-over-year).
2021: Revenue of $1.1M, expenses of $1.1M, and assets of $1.9M (revenue -46.5% year-over-year).
2021: Revenue of $2.0M, expenses of $2.1M, and assets of $847K (revenue -5.1% year-over-year).
2020: Revenue of $2.1M, expenses of $2.2M, and assets of $1.5M (revenue +3.5% year-over-year).
2019: Revenue of $2.1M, expenses of $2.1M, and assets of $3.3M (revenue +17.3% year-over-year).
2018: Revenue of $1.8M, expenses of $1.8M, and assets of $1.8M (revenue +111.7% year-over-year).
2017: Revenue of $829K, expenses of $631K, and assets of $598K.
2016: Revenue of $0, expenses of $0, and assets of $1.
2015: Revenue of $0, expenses of $98, and assets of $1 (revenue -100.0% year-over-year).
2014: Revenue of $152K, expenses of $156K, and assets of $98 (revenue +635.3% year-over-year).
2013: Revenue of $21K, expenses of $21K, and assets of $5K (revenue -45.0% year-over-year).
2012: Revenue of $37K, expenses of $37K, and assets of $5K (revenue -76.8% year-over-year).
2011: Revenue of $162K, expenses of $187K, and assets of $25K.

Data Sources and Methodology

This transparency report for Regenmed Development Organization is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.

IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.

Disclaimer

AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.